Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$5.74M | -$9.80M | -$12.8M | -$31.7M | -$40.0M | -$84.2M |
| Net income | -$5.75M | -$9.67M | -$12.6M | -$31.6M | -$36.1M | -$77.6M |
| EPS (diluted) | -$0.65 | -$1.01 | -$0.63 | -$1.19 | -$1.18 | -$2.31 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4.44M | -$7.47M | -$11.5M | -$29.8M | -$29.2M | -$37.0M |
| Capital expenditures | — | $74.0K | $394K | $63.0K | $116K | $71.0K |
| Free cash flow | — | -$7.55M | -$11.9M | -$29.9M | -$29.4M | -$37.1M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $25.6M | $17.3M | $42.1M | $88.2M | $31.7M | $353M |
| Total assets | — | $18.3M | $44.3M | $94.6M | $152M | $781M |
| Total liabilities | — | $1.64M | $2.77M | $4.21M | $6.31M | $10.1M |
| Shareholders' equity | -$7.04M | -$15.1M | $41.5M | $90.4M | $146M | $770M |
| Retained earnings | -$17.6M | -$27.2M | -$39.9M | -$71.5M | -$108M | -$185M |
| Shares (wtd avg diluted) | 8.79M | 9.57M | 20.0M | 26.6M | 30.5M | 33.5M |
Every figure is extracted from BELITE BIO, INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.